The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA Warning Letter Breakdown: Testing the Line Between Consumer Wellness Claims and Regulated Physiologic Measurement Functions in Wearables Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA Warning Letter to EvexiPEL's Pellet Supplier, Farmakeio BHRT Options Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement Stevens & Lee